JP6637652B2 - 抗腫瘍剤の選択方法およびその抗腫瘍剤が含有するsiRNA - Google Patents
抗腫瘍剤の選択方法およびその抗腫瘍剤が含有するsiRNA Download PDFInfo
- Publication number
- JP6637652B2 JP6637652B2 JP2014237060A JP2014237060A JP6637652B2 JP 6637652 B2 JP6637652 B2 JP 6637652B2 JP 2014237060 A JP2014237060 A JP 2014237060A JP 2014237060 A JP2014237060 A JP 2014237060A JP 6637652 B2 JP6637652 B2 JP 6637652B2
- Authority
- JP
- Japan
- Prior art keywords
- expression
- seq
- mdm2
- mdm4
- sina
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims description 33
- 108020004459 Small interfering RNA Proteins 0.000 title claims description 23
- 238000000034 method Methods 0.000 title claims description 13
- 230000014509 gene expression Effects 0.000 claims description 124
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 79
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 79
- 102000017274 MDM4 Human genes 0.000 claims description 73
- 108050005300 MDM4 Proteins 0.000 claims description 73
- 210000004881 tumor cell Anatomy 0.000 claims description 56
- 244000089409 Erythrina poeppigiana Species 0.000 claims description 51
- 235000009776 Rathbunia alamosensis Nutrition 0.000 claims description 51
- 101150054147 sina gene Proteins 0.000 claims description 51
- 239000003112 inhibitor Substances 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 60
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 28
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 27
- 230000002401 inhibitory effect Effects 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 13
- 230000001629 suppression Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108700025694 p53 Genes Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000009437 off-target effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108091027548 SiDNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 102000048958 human TP53 Human genes 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- -1 shDNA Proteins 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
CAGCCAUCAACUUCUAGUN (配列番号1)
GUCGGUAGUUGAAGAUCAN (配列番号2)
また、前記MDM4を抑制する抑制剤が、以下の配列からなる二重鎖部分を有するsiNAからなる群:
CCCUCUCUAUGAUAUGCUN (配列番号3)
GGGAGAGAUACUAUACGAN (配列番号4)
GGUCAUGCACUAUUUAGGN (配列番号5)
CCAGUACGUGAUAAAUCCN (配列番号6)
GGUGAAGCAACUUUAUGAN (配列番号7)
CCACUUCGUUGAAAUACUN (配列番号8)
CAACUAUACACCUAGAAGN (配列番号9)
GUUGAUAUGUGGAUCUUCN (配列番号10)
GUGAUGAUACCGAUGUAGN (配列番号11)
CACUACUAUGGCUACAUCN (配列番号12)
より選択されるsiNAを含有してもよい。。
CAGCCAUCAACUUCUAGUN (配列番号1)
GUCGGUAGUUGAAGAUCAN (配列番号2)
本発明にかかるさらなる一実施態様は、MDM4の発現を抑制するためのsiNAであって、以下の配列からなる二重鎖部分を有するsiNAからなる群:
CCCUCUCUAUGAUAUGCUN (配列番号3)
GGGAGAGAUACUAUACGAN (配列番号4)
GGUCAUGCACUAUUUAGGN (配列番号5)
CCAGUACGUGAUAAAUCCN (配列番号6)
GGUGAAGCAACUUUAUGAN (配列番号7)
CCACUUCGUUGAAAUACUN (配列番号8)
CAACUAUACACCUAGAAGN (配列番号9)
GUUGAUAUGUGGAUCUUCN (配列番号10)
GUGAUGAUACCGAUGUAGN (配列番号11)
CACUACUAUGGCUACAUCN (配列番号12)
より選択されるsiNAである。
CAGCCAUCAACUUCUAGUN (配列番号1)
GUCGGUAGUUGAAGAUCAN (配列番号2)
CCCUCUCUAUGAUAUGCUN (配列番号3)
GGGAGAGAUACUAUACGAN (配列番号4)
本発明にかかるさらなる一実施態様は、上記siNAペアを含有する抗腫瘍剤である。
本発明の一実施態様において、腫瘍を治療するための薬剤の選択方法は、採取した腫瘍細胞のMDM2および/またはMDM4の発現を調べる工程と、採取した腫瘍細胞においてMDM4の発現が高い場合、または採取した腫瘍細胞においてMDM2の発現が低い場合、MDM2および/またはMDM4の発現を抑制する抑制剤を抗腫瘍剤として選択し、採取した腫瘍細胞においてMDM4の発現が低い場合、または採取した腫瘍細胞においてMDM2の発現が高い場合、MDM2の発現を抑制する抑制剤を抗腫瘍剤として選択する工程とを含む。
本発明のsiNAは、腫瘍細胞においてMDM4の発現が高い場合における、MDM2および/またはMDM4の発現を抑制するためのsiNAであって、MDM2の発現を抑制するためのsiNAの二重鎖部分が、
1489:
CAGCCAUCAACUUCUAGUN (配列番号1)
GUCGGUAGUUGAAGAUCAN (配列番号2)
であって、
MDM4の発現を抑制するためのsiNAの二重鎖部分が、以下の配列を有するsiNAからなる群:
452:
CCCUCUCUAUGAUAUGCUN (配列番号3)
GGGAGAGAUACUAUACGAN (配列番号4)
317:
GGUCAUGCACUAUUUAGGN (配列番号5)
CCAGUACGUGAUAAAUCCN (配列番号6)
347:
GGUGAAGCAACUUUAUGAN (配列番号7)
CCACUUCGUUGAAAUACUN (配列番号8)
788:
CAACUAUACACCUAGAAGN (配列番号9)
GUUGAUAUGUGGAUCUUCN (配列番号10)
1036:
GUGAUGAUACCGAUGUAGN (配列番号11)
CACUACUAUGGCUACAUCN (配列番号12)
より選択される。MDM2とMDM4の発現の一方を抑制する場合、いずれか一方の配列を用いて発現を抑制すればよく、MDM2とMDM4の発現の両方を抑制する場合、両方の配列を用いて発現を抑制すればよい。
本発明のsiNAは、腫瘍細胞においてMDM2の発現が高い場合における、MDM2の発現を抑制するためのsiNAであって、MDM2の発現を抑制するためのsiRNAが、
1489:
CAGCCAUCAACUUCUAGUN (配列番号1)
GUCGGUAGUUGAAGAUCAN (配列番号2)
である。
本発明に係る抗腫瘍剤はまた、有効成分である核酸の他、必要に応じて、一般に用いられる各種成分をさらに含み得るものであり、例えば、1種以上の医薬的に許容され得る賦形剤、崩壊剤、希釈剤、滑沢剤、着香剤、着色剤、甘味剤、矯味剤、懸濁化剤、湿潤剤、乳化剤、分散剤、補助剤、防腐剤、緩衝剤、結合剤、安定剤、コーティング剤などを含み得る。
各腫瘍細胞株(表1参照)の細胞抽出液を用いて、ウエスタンブロッティングを行った。
MDM2抑制配列として(1)で選択された配列(643、691、830、1489、2381、6068)を有するsiRNA及びキメラsiNAについて、MDM2抑制によるp53の発現抑制解除を通じた増殖抑制活性を調べた。
MDM4発現抑制配列として(1)で選択された配列(317、347、452、788、1036)を有するキメラsiNAについて、MDM4発現抑制によるp53の発現抑制解除を通じた増殖抑制活性を調べた。
表1に示した細胞のうち、野生型のp53遺伝子を有しているMCF−7からC32TGまでの細胞株について、MDM2またはMDM4の発現を抑制し、それに伴う細胞残存率を測定した。具体的な実験方法は(2)(3)と同様にし、コントロールの配列(siNaito-1)の細胞残存率を100%としたときの相対的な細胞残存率を算出した。なお、発現抑制にはキメラsiNA分子を用い、MDM2については配列1068及び1489、MDM4については配列452及び1036を用いた。その結果を図5に示す。
Claims (10)
- 腫瘍を有する患者を治療するための抗腫瘍剤の選択方法であって、
前記患者から採取した腫瘍細胞のMDM4の発現を調べる工程と、
前記採取した腫瘍細胞においてMDM4の発現が高い場合、MDM2の発現を抑制する抑制剤を抗腫瘍剤として選択する工程と、
を含む抗腫瘍剤の選択方法。 - 前記腫瘍細胞が、正常に発現制御される野生型p53を有している、請求項1に記載の抗腫瘍剤の選択方法。
- 前記MDM2を抑制する抑制剤が、以下の配列からなる二重鎖部分を有するsiNAを含有する、請求項1または2に記載の抗腫瘍剤の選択方法。
CAGCCAUCAACUUCUAGUN (配列番号1)
GUCGGUAGUUGAAGAUCAN (配列番号2) - MDM2の発現を抑制するためのsiNAであって、以下の配列からなる二重鎖部分を有するsiNA。
CAGCCAUCAACUUCUAGUN (配列番号1)
GUCGGUAGUUGAAGAUCAN (配列番号2) - MDM4の発現を抑制するためのsiNAであって、以下の配列からなる二重鎖部分を有するsiNAからなる群:
CCCUCUCUAUGAUAUGCUN (配列番号3)
GGGAGAGAUACUAUACGAN (配列番号4)
GGUCAUGCACUAUUUAGGN (配列番号5)
CCAGUACGUGAUAAAUCCN (配列番号6)
GGUGAAGCAACUUUAUGAN (配列番号7)
CCACUUCGUUGAAAUACUN (配列番号8)
CAACUAUACACCUAGAAGN (配列番号9)
GUUGAUAUGUGGAUCUUCN (配列番号10)
GUGAUGAUACCGAUGUAGN (配列番号11)
CACUACUAUGGCUACAUCN (配列番号12)
より選択されるsiNA。 - MDM2およびMDM4の発現を同時に抑制するためのsiNAペアであって、
MDM2の発現を抑制するためのsiNAが、請求項4に記載のsiNAであって、
MDM4の発現を抑制するためのsiNAが、請求項5に記載のsiNAであるsiRNAペア。 - 下記配列からなる、請求項6に記載のsiNAペア。
CAGCCAUCAACUUCUAGUN (配列番号1)
GUCGGUAGUUGAAGAUCAN (配列番号2)
CCCUCUCUAUGAUAUGCUN (配列番号3)
GGGAGAGAUACUAUACGAN (配列番号4) - 請求項6または7に記載のsiNAペアを含有する抗腫瘍剤。
- MDM4の発現が高い腫瘍細胞に対する抗腫瘍剤であって、MDM2の発現抑制剤を有効成分として含有する抗腫瘍剤。
- 前記MDM2の発現抑制剤が、請求項4に記載のsiNAを含有する、請求項9に記載の抗腫瘍剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014237060A JP6637652B2 (ja) | 2014-11-21 | 2014-11-21 | 抗腫瘍剤の選択方法およびその抗腫瘍剤が含有するsiRNA |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014237060A JP6637652B2 (ja) | 2014-11-21 | 2014-11-21 | 抗腫瘍剤の選択方法およびその抗腫瘍剤が含有するsiRNA |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016099252A JP2016099252A (ja) | 2016-05-30 |
JP6637652B2 true JP6637652B2 (ja) | 2020-01-29 |
Family
ID=56076878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014237060A Active JP6637652B2 (ja) | 2014-11-21 | 2014-11-21 | 抗腫瘍剤の選択方法およびその抗腫瘍剤が含有するsiRNA |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6637652B2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6315634B2 (ja) | 2016-05-18 | 2018-04-25 | 株式会社アマダホールディングス | 複合加工システム及びレーザ切断加工方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2617877T3 (es) * | 2007-08-27 | 2017-06-20 | 1Globe Health Institute Llc | Composiciones de ARN interferente asimétrico y uso de las mismas |
JP5510783B2 (ja) * | 2009-09-18 | 2014-06-04 | 独立行政法人産業技術総合研究所 | 薬剤が細胞に与える影響を評価するシステム |
AU2012253339B2 (en) * | 2011-05-11 | 2016-03-31 | Sanofi | Spiro-oxindole MDM2 antagonists |
CN104144695A (zh) * | 2012-02-15 | 2014-11-12 | 爱勒让治疗公司 | ***交联的和硫醚交联的拟肽大环化合物 |
-
2014
- 2014-11-21 JP JP2014237060A patent/JP6637652B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016099252A (ja) | 2016-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lang et al. | MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA | |
Wang et al. | miRNA-regulated delivery of lincRNA-p21 suppresses β-catenin signaling and tumorigenicity of colorectal cancer stem cells | |
Zhou et al. | lncRNA SNHG16 promotes glioma tumorigenicity through miR-373/EGFR axis by activating PI3K/AKT pathway | |
Daige et al. | Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer | |
US20200056177A1 (en) | Long non-coding rna used for anticancer therapy | |
Yang et al. | Sp1-mediated microRNA-182 expression regulates lung cancer progression | |
Wu et al. | MicroRNA-199a-3p regulates endometrial cancer cell proliferation by targeting mammalian target of rapamycin (mTOR) | |
Zhang et al. | Decreased expression of microRNA-320a promotes proliferation and invasion of non-small cell lung cancer cells by increasing VDAC1 expression | |
Bao et al. | miR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2 | |
Cai et al. | MiR-17-5p promotes cervical cancer cell proliferation and metastasis by targeting transforming growth factor-β receptor 2. | |
Gao et al. | MicroRNA‐107 is downregulated and having tumor suppressive effect in breast cancer by negatively regulating brain‐derived neurotrophic factor | |
Zhao et al. | miR-1278 sensitizes nasopharyngeal carcinoma cells to cisplatin and suppresses autophagy via targeting ATG2B | |
Gao et al. | miR-200a inhibits tumor proliferation by targeting AP-2γ in neuroblastoma cells | |
Zhang et al. | A miR-124/ITGA3 axis contributes to colorectal cancer metastasis by regulating anoikis susceptibility | |
Liu et al. | MiR-144 inhibits tumor growth and metastasis in osteosarcoma via dual-suppressing RhoA/ROCK1 signaling pathway | |
Zheng et al. | MicroRNA-4651 targets bromodomain-containing protein 4 to inhibit non-small cell lung cancer cell progression | |
Yan et al. | BAG3 promotes proliferation of ovarian cancer cells via post-transcriptional regulation of Skp2 expression | |
JP6727381B2 (ja) | Hpv感染に係わる癌の治療用組成物 | |
US20110060029A1 (en) | Method of treating cancer by modulating epac | |
JP6919891B2 (ja) | Epstein−Barrウイルス関連癌に特異的な抗腫瘍剤 | |
JP6637652B2 (ja) | 抗腫瘍剤の選択方法およびその抗腫瘍剤が含有するsiRNA | |
Lin et al. | An NF90/long noncoding RNA-LET/miR-548k feedback amplification loop controls esophageal squamous cell carcinoma progression | |
JP4054844B2 (ja) | 副作用のないRNAi医薬 | |
JP5887413B2 (ja) | 非小細胞肺癌におけるtm4sf4の発現または活性を調節することによって癌細胞の放射線耐性ならびに増殖、転移および浸潤を低減させる方法 | |
Yao et al. | Knockdown of β-catenin expression inhibits neuroblastoma cell growth in vitro and in vivo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171115 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180711 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180821 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181022 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190618 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190619 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20190704 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190704 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191126 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191223 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6637652 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |